<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>中康开思 | wechat-feeds</title><link>http://MzUyODM5NzU3Ng.favicon.privacyhide.com/favicon.ico</link><description>基于数据科学，提供高效便捷的健康产业数据情报，连接数据与决策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 08 Mar 2021 16:26:16 +0800</pubDate><image><url>http://MzUyODM5NzU3Ng.favicon.privacyhide.com/favicon.ico</url><title>中康开思 | wechat-feeds</title><link>http://MzUyODM5NzU3Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>广为医药新药受理号申报最多 | 药品审评进度周周看（3.1-3.7）</title><link>https://mp.weixin.qq.com/s/XsnUihdh-Il-rTi2PW6HjA</link><description></description><content:encoded><![CDATA[广为医药新药受理号申报最多 | 药品审评进度周周看（3.1-3.7）]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:21:06 +0800</pubDate></item><item><title>新药申报比例上升 | 药品审评进度周周看（2.22-2.28）</title><link>https://mp.weixin.qq.com/s/7y2d5fMU9_m5VSf26lSHxA</link><description></description><content:encoded><![CDATA[新药申报比例上升 | 药品审评进度周周看（2.22-2.28）]]></content:encoded><pubDate>Mon, 01 Mar 2021 15:40:01 +0800</pubDate></item><item><title>【开思系统数据更新】2020年第四季度零售市场数据更新上线！</title><link>https://mp.weixin.qq.com/s/2-kUsMEMdGRRI-rtkeRzAg</link><description></description><content:encoded><![CDATA[【开思系统数据更新】2020年第四季度零售市场数据更新上线！]]></content:encoded><pubDate>Mon, 01 Mar 2021 15:40:01 +0800</pubDate></item><item><title>西安京西双鹤受理号申报最多 | 药品审评进度周周看（2.14-2.21）</title><link>https://mp.weixin.qq.com/s/lVqeIFuusrEgiDVVaK55OA</link><description></description><content:encoded><![CDATA[西安京西双鹤受理号申报最多 | 药品审评进度周周看（2.14-2.21）]]></content:encoded><pubDate>Mon, 22 Feb 2021 15:40:23 +0800</pubDate></item><item><title>中康CMH | 冰火两重天——栉风沐雨中毅行的药品零售市场解读</title><link>https://mp.weixin.qq.com/s/CaJL9SA64mERF6E7KgfrcQ</link><description></description><content:encoded><![CDATA[中康CMH | 冰火两重天——栉风沐雨中毅行的药品零售市场解读]]></content:encoded><pubDate>Mon, 22 Feb 2021 15:40:23 +0800</pubDate></item><item><title>科伦药业受理号申报最多 | 药品审评进度周周看（2.8-2.14）</title><link>https://mp.weixin.qq.com/s/3S8SYY2lBomDF5VbdA7IsA</link><description></description><content:encoded><![CDATA[科伦药业受理号申报最多 | 药品审评进度周周看（2.8-2.14）]]></content:encoded><pubDate>Fri, 19 Feb 2021 14:37:13 +0800</pubDate></item><item><title>葛兰素史克受理号申报最多 | 药品审评进度周周看（2.1-2.7）</title><link>https://mp.weixin.qq.com/s/sSQuzWykV2Q8hfI9iSs_yA</link><description></description><content:encoded><![CDATA[葛兰素史克受理号申报最多 | 药品审评进度周周看（2.1-2.7）]]></content:encoded><pubDate>Mon, 08 Feb 2021 14:31:29 +0800</pubDate></item><item><title>中康CMH | 阿斯利康继续领跑——2020前三季度中国医院市场回顾 ​</title><link>https://mp.weixin.qq.com/s/AMGEDyQUB0wKyV5-rjFPEQ</link><description></description><content:encoded><![CDATA[中康CMH | 阿斯利康继续领跑——2020前三季度中国医院市场回顾 ​]]></content:encoded><pubDate>Mon, 08 Feb 2021 14:31:29 +0800</pubDate></item><item><title>开拓药业新药受理号申报最多 | 药品审评进度周周看（1.25-1.31）</title><link>https://mp.weixin.qq.com/s/JizalgIrqrKK36xG274kig</link><description></description><content:encoded><![CDATA[开拓药业新药受理号申报最多 | 药品审评进度周周看（1.25-1.31）]]></content:encoded><pubDate>Mon, 01 Feb 2021 14:34:43 +0800</pubDate></item><item><title>辉瑞受理号申报最多 | 药品审评进度周周看（1.18-1.24）</title><link>https://mp.weixin.qq.com/s/0bxQoIJSb23Qour2G_kkAg</link><description></description><content:encoded><![CDATA[辉瑞受理号申报最多 | 药品审评进度周周看（1.18-1.24）]]></content:encoded><pubDate>Mon, 25 Jan 2021 16:06:01 +0800</pubDate></item><item><title>【开思系统数据更新】终端品类分析11月份数据更新上线！</title><link>https://mp.weixin.qq.com/s/Ds8x_8jdptYK-1s21WVK7g</link><description></description><content:encoded><![CDATA[【开思系统数据更新】终端品类分析11月份数据更新上线！]]></content:encoded><pubDate>Mon, 25 Jan 2021 16:06:01 +0800</pubDate></item><item><title>信立泰新药受理号申报最多 | 药品审评进度周周看（1.11-1.17）</title><link>https://mp.weixin.qq.com/s/3g63MgTAJzupEQaW_B_Q1Q</link><description></description><content:encoded><![CDATA[信立泰新药受理号申报最多 | 药品审评进度周周看（1.11-1.17）]]></content:encoded><pubDate>Mon, 18 Jan 2021 15:49:13 +0800</pubDate></item><item><title>酚酞片禁售！或将释放十亿级潜力增量市场！</title><link>https://mp.weixin.qq.com/s/X39d1A6GDRiRE4WfB3X8ow</link><description></description><content:encoded><![CDATA[酚酞片禁售！或将释放十亿级潜力增量市场！]]></content:encoded><pubDate>Mon, 18 Jan 2021 15:49:13 +0800</pubDate></item><item><title>中康CMH | 咽喉用药触底反弹！蓝芩、复方鱼腥草、冬凌草口服液驱动增长！</title><link>https://mp.weixin.qq.com/s/heZFwwx4QnC1oexto6f_7w</link><description></description><content:encoded><![CDATA[中康CMH | 咽喉用药触底反弹！蓝芩、复方鱼腥草、冬凌草口服液驱动增长！]]></content:encoded><pubDate>Mon, 18 Jan 2021 15:49:13 +0800</pubDate></item><item><title>安科生物新药受理号申报最多 | 药品审评进度周周看（1.4-1.10）</title><link>https://mp.weixin.qq.com/s/_O1AziadfSy8PoYTGkmymA</link><description></description><content:encoded><![CDATA[安科生物新药受理号申报最多 | 药品审评进度周周看（1.4-1.10）]]></content:encoded><pubDate>Mon, 11 Jan 2021 16:18:10 +0800</pubDate></item><item><title>中康CMH | 益生菌品类发展概况：百家争鸣，鏖战蓝海</title><link>https://mp.weixin.qq.com/s/mqfWIVgY_moUVNYf6UYwYQ</link><description></description><content:encoded><![CDATA[中康CMH | 益生菌品类发展概况：百家争鸣，鏖战蓝海]]></content:encoded><pubDate>Mon, 11 Jan 2021 16:18:10 +0800</pubDate></item><item><title>默沙东受理号申报最多 | 药品审评进度周周看（12.28-1.3）</title><link>https://mp.weixin.qq.com/s/pb3tofUoNHUYQjfY3LT9_Q</link><description></description><content:encoded><![CDATA[默沙东受理号申报最多 | 药品审评进度周周看（12.28-1.3）]]></content:encoded><pubDate>Mon, 04 Jan 2021 15:59:50 +0800</pubDate></item><item><title>【开思系统数据更新】终端品类分析10月份数据更新上线！</title><link>https://mp.weixin.qq.com/s/cemRbIo-6IpGrgxcGnoAVg</link><description></description><content:encoded><![CDATA[【开思系统数据更新】终端品类分析10月份数据更新上线！]]></content:encoded><pubDate>Mon, 04 Jan 2021 15:59:50 +0800</pubDate></item><item><title>贝达药业新药受理号申报最多 | 药品审评进度周周看（12.21-12.27）</title><link>https://mp.weixin.qq.com/s/cGXKR-cvN7fdf5guVd2ldg</link><description></description><content:encoded><![CDATA[贝达药业新药受理号申报最多 | 药品审评进度周周看（12.21-12.27）]]></content:encoded><pubDate>Mon, 04 Jan 2021 15:59:50 +0800</pubDate></item></channel></rss>